GSRLX
Price
$13.28
Change
+$0.17 (+1.30%)
Updated
Sep 11 closing price
Net Assets
401.73M
VSTSX
Price
$360.74
Change
+$3.02 (+0.84%)
Updated
Sep 11 closing price
Net Assets
2.34T
Interact to see
Advertisement

GSRLX vs VSTSX

GSRLX vs VSTSX Comparison Chart in %
View a ticker or compare two or three
VS
GSRLX vs. VSTSX commentary
Sep 12, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GSRLX is a Buy and VSTSX is a Buy.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
VSTSX has more cash in the bank: 2.34T vs. GSRLX (402M). GSRLX pays higher dividends than VSTSX: GSRLX (1.36) vs VSTSX (1.05). GSRLX was incepted earlier than VSTSX: GSRLX (19 years) vs VSTSX (10 years). GSRLX (0.93) is less costly to investors than VSTSX (0.01). GSRLX is a more actively managed with annual turnover of: 35.00 vs. VSTSX (3.00). GSRLX has a lower initial minimum investment than VSTSX: GSRLX (1000000) vs VSTSX (5000000000). VSTSX annual gain was more profitable for investors over the last year : 14.99 vs. GSRLX (1.53). VSTSX return over 5 years is better than : 63.04 vs. GSRLX (1.66).
GSRLXVSTSXGSRLX / VSTSX
Total Expense Ratio0.690.016,900%
Annual Report Gross Expense Ratio0.930.019,300%
Fund Existence19 years10 years-
Gain YTD12.35811.351109%
Front LoadN/AN/A-
Min. Initial Investment100000050000000000%
Min. Initial Investment IRAN/AN/A-
Net Assets402M2.34T0%
Annual Yield % from dividends1.361.05130%
Returns for 1 year1.5314.9910%
Returns for 3 years14.9368.8922%
Returns for 5 years1.6663.043%
Returns for 10 years-21.90245.06-9%
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
SGRX1.680.25
+17.48%
Sangrix Inc.
CLOV4.820.11
+2.34%
Clover Health Investments Corp
WKEY6.360.06
+0.95%
WISeKey International Holding Ltd
JBS12.59-0.03
-0.24%
JBS NV Ordinary Shares - Class A
IRD6.04-0.03
-0.49%
Opus Genetics Inc